Tag Archives | cancer vaccines immunotherapy

Biotech Rally Moving Toward April Highs: ASCO and M&A Provides Underlying Support…Update-1

Update June 1… After Close Biotech Holds…Uh oh CNBC is talking about biotech. IBB 281.18, XBI 58.18 This stealth rally has been going steady for two weeks but now CNBC and its “Fast Money” show are talking up biotech so is this a jinx? And saying “party over” when the rally just started?? “Options Action” […]

Continue Reading 0

Biotech Rally Fades But Plenty of Big Movers: ASCO June 6

Biotech Rally Fades after Five Days: IBB down 0.49%, XBI down 1% Biotech stocks were weak at the onset and could not come back but the sector is still up about 7% over five days. Stocks were mixed on thursday and healthcare was weak with the XLV flat at $70.84. The big mover was Alnylam […]

Continue Reading 0

Rayno Biopharmaceuticals Update 3/30-Stuck in a Trading Range with Upside Opportunities

Rayno Biopharmaceutical Portfolio Update- Biotechs with Upside Opportunity Caution No Rush to “Load Up” in a Bear Market Since Mid-January all of our previous portfolios were placed on hold and we recommended four new positions as long term holds. Here are initial prices and the current performance: Abbvie (ABBV) Started at $56.49 now at $56.96 […]

Continue Reading 0

Biotech Stocks Lag Today’s Rally: S&P 500 Erases February Losses But Still Down 4.4% YTD…Update-1

2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up 4.63% to $22.62. Large cap biopharma joined the sell-off and Fidelity Select Biotechnology Portfolio (FBIOX) […]

Continue Reading 0

Large Cap Biopharma Winners and Losers 2015-16: Which Stocks Can Beat the ETFs?… Part 2

Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our portfolio after the J.P.Morgan Healthcare Conference. Here are some parameters to watch that should help in stock picking: Stock […]

Continue Reading 0

Biotech Bear Market Update: Barely Bouncing Off the Bottom

Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35%         XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally then faded with the IBB up 0.625 % […]

Continue Reading 0

Valuation Models for Large Cap Biopharma Stocks in a Bear Market

 Valuation Models for Large Cap Biopharma Stocks Can Robust Drug Pipelines Deliver Future EPS Growth? This is a follow-up of our post on 1/8/16 Large Cap Biopharmaceuticals which looks at valuation models and stock performance of selected companies after the J.P.Morgan Healthcare Conference and then again after 2015 earnings reports over the next few weeks. Which […]

Continue Reading 0

Bio Investor Forum #3: Finding Value in Biotech Innovation

Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly represented in the industry. And the panel sessions on topics such as Venture Capital, Government Policies and […]

Continue Reading 0

Biotech ETFs Up YTD But 12% Losses in August Creates Downtrend…Update-2.. 9/4

Update -2… 9/8 Rally Time Today Forecasted by Friday’s Action ETF Summary -One month and YTD % FBT (12.36), +9.2% IBB (8.9), +11.3% XBI (10.12), +17.27% The five star Fidelity Select Biotech Portfolio (FBIOX) pretty much tracks the IBB up 11.66% YTD and down (8.52) for one month. Three relatively new top ten mid-cap holdings […]

Continue Reading 0

Biotech Breakdown Leg #2: Another Nasty 4% Hit

Nowhere to Hide in Another 4% Correction 8/25/15 Futures Look Promising at 11p EDT; NIKKEI 225 UP 4.8% Today’s market reached epic proportions of volatility and extremes exacerbated by a DOW opening “flash crash” off 1100 points that distorted faith in market mechanics. Several long time market experts opined that the distortions and panic today […]

Continue Reading 0

Biotech Breakdown: Seeking Relief Today

At Close: IBB down 2.35% to 342 at May bottom, XBI up 0.64% to 218 —- Two Hours to Go 2:15p EDT, NASDAQ Down 1.79% at 4792, IBB at $349 Biotech Breakdown: Relief Today Or Another Head Fake? Biotech stocks are trying to hold the May lows with the IBB at $342 but now at $349. […]

Continue Reading 0

FED Rallies Market But Biotech Stocks Are Lagging…Update-1

Update-1 Stealth End of Month Rally Stops Biotech Slide IBB up 3.4% In July and up 1% on Last Day Stocks roared out of the box on Friday but could not hold and ended flat. NASDAQ Up 2.3% for July. Most biotech stocks were green and momentum players came back in to support their favorites: BLUE, JUNO, KITE, […]

Continue Reading 0

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0

Biotech Stocks Lose Momentum with Greece Crisis; Blockbuster Immunotherapy Deal

Biotech Stocks in Broad Sell-Off The biotech sector is usually immune to macro events but today the crisis in Greece gave investors an excuse to take profits. Many biotech stocks and ETFs were down over 3% faring worse than the NASDAQ down 2.4%. The sector, as tracked by IBB, is still up 18.87% YTD after […]

Continue Reading 0

Rayno Biopharma Stocks at ASCO: ARRY, CLVS, RXDX

Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers. […]

Continue Reading 0